openPR Logo
Press release

Hyperhidrosis Therapeutics Pipeline to Witness Remarkable Growth due to Increased Number of Pipeline Candidates by Drug Developers | Top players are Brickell Biotech, Inc., Medytox Inc., MediTox s.r.o., Allergan, Dermira, Inc., Atacama Therapeutics, Inc.,

06-07-2019 12:22 PM CET | Health & Medicine

Press release from: Pharma Proff

Hyperhidrosis Therapeutics Pipeline to Witness Remarkable

Hyperhidrosis refers to excessive sweating from some body parts, including palms, heads, feet, or underarms. It is mainly categorized into two types: primary hyperhidrosis and secondary hyperhidrosis. It can be diagnosed by physical examinations of the excessively sweating body parts and by conducting a sweat test. The available treatment options for hyperhidrosis include Botulinum toxin, prescription medicines, antiperspirants, and iontophoresis.

Download the sample report at: https://www.pharmaproff.com/request-sample/1223

Botox injection (Allergan plc) and Qbrexza (Dermira Inc.) are amongst the U.S. Food and Drug Administration (USFDA) approved therapies for hyperhidrosis.

According to the research findings, majority of pipeline drug candidates are being developed for topical administration. It has been observed that the topical route of administration is convenient, less risk of systemic infections, and inexpensive in nature, and also provides improved patient’s compliance. Moreover, the entire administered dose reaches the target glands and immediately starts showing its effects on hyperhidrosis.

Get the detailed analysis at: https://www.pharmaproff.com/report/hyperhidrosis-therapeutics-pipeline-analysis

Companies that are involved in developing therapeutics for hyperhidrosis have shown positive clinical results in various phases of drug development. For instance, in June 2016, Dermira Inc. announced positive clinical results of phase III trial of DRM04 for the treatment of patients with hyperhidrosis. The results of the study concluded that the primary endpoints were achieved and patients showed statistically significant improvement as compared to placebo.

Make enquiry before purchase at: https://www.pharmaproff.com/enquiry/1223

Botox injection and Qbrexa are most commonly drugs used for the treatment of hyperhidrosis. These drugs hold significant share in the global hyperhidrosis market. Therefore, with the emergence of late- and mid-stage pipeline products, the overall hyperhidrosis therapeutics market is expected to grow significantly in the upcoming years.

Some of the key players involved in the development of hyperhidrosis therapeutics in the late- and mid-stage include Brickell Biotech Inc., Meditox Co. Ltd., Allergan plc, Dermira Inc., Atacama Therapeutics Inc., Kaken Pharmaceutical Co. Ltd., Revance Therapeutics Inc., HUGEL Inc., Prime Therapeutics LLC, and Roivant Sciences Ltd.

Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hyperhidrosis Therapeutics Pipeline to Witness Remarkable Growth due to Increased Number of Pipeline Candidates by Drug Developers | Top players are Brickell Biotech, Inc., Medytox Inc., MediTox s.r.o., Allergan, Dermira, Inc., Atacama Therapeutics, Inc., here

News-ID: 1767869 • Views: 423

More Releases from Pharma Proff

Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates. IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates. Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome. Download the sample report at: https://www.pharmaproff.com/request-sample/1189 Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances

All 5 Releases


More Releases for Therapeutics

Lipodystrophy Therapeutics- Pipeline Analysis 2018 | Ionis Pharmaceuticals, Inc. …
Lipodystrophy is a rare medical condition which involves problems with fat production, usage, and storage. It is categorized into two types; congenital and acquired lipodystrophy. Download the sample report @ https://www.pharmaproff.com/request-sample/1077 Congenital lipodystrophies include congenital generalized lipodystrophy, familial partial lipodystrophy, and marfanoid progeroid lipodystrophy syndrome; while acquired lipodystrophy includes acquired partial lipodystrophy, acquired generalized lipodystrophy, centrifugal abdominal lipodystrophy, lipoatrophia annularis, localized lipodystrophy and HIV-associated lipodystrophy. Get the detailed analysis @ https://www.pharmaproff.com/report/lipodystrophy-therapeutics-pipeline-analysis The
Dravet Syndrome Therapeutics- Pipeline Analysis 2018 | Zogenix, Inc., Ovid Thera …
Dravet syndrome is a form of severe myoclonic epilepsy that occurs in infants during their first year of age. If left untreated, it can be associated with other types of seizures, and status epilepticus. Children having Dravet syndrome are generally observed with poor cognitive skills and hyperactivity. Download the sample report @ https://www.pharmaproff.com/request-sample/1098 It severely affects the person’s quality of life and around 10-20% of the patient are estimated to die due
Pontine Glioma Therapeutics- Pipeline Analysis 2018 | Y-mAbs Therapeutics, Inc.
Pontine glioma is a malignant tumour which develops from the brain stem cells. Based on the grade of growth, it is categorized into anaplastic astrocytomas and glioblastoma multiforme (GBM). Download the sample report @ https://www.pharmaproff.com/request-sample/1117 Pontine glioma is more prevalent in children than adults. The common signs and symptoms of pontine glioma are squints, swallowing problems, slurred speech, facial weakness, abnormal gait, difficulty in writing and changes in personality and behaviour.
Rheumatology Therapeutics Market
Global Rheumatology Therapeutics Market: Snapshot A rising elderly population and increasing allocations for research and development of new drugs is what is serving to drive growth in the global rheumatology therapeutics market. This has led to the emergence of many new drugs. Their swift approvals by the appropriate authorities has also led to the growth in the market. A report by Transparency Market Research uncovers after in-depth study that the global rheumatology
Bone Degeneration Therapeutics Market
Bone degeneration is characterized by deterioration of articular cartilage covering the joints. Cartilage aids free movement of the joint without any resistance. Reduction in flexibility of the joint due to deterioration of cartilage leads to inflammation, compressed nerves, and pain. Aging is one of the natural causes of bone degeneration, which is also fueled by several conditions such as injuries, congenital disorders, diabetes, and obesity. Symptoms of degenerative bone disorders
Global Dyslipidemia Therapeutics Market
Dyslipidemia is one of the metabolic disorder, which is described by unbalanced level and thickness of lipoproteins and triglycerides. The disorder also includes protein deficiency and over production. These disorders can be caused by increase in the serum total cholesterol, triglyceride concentrations, and low-density lipoprotein (LDL) cholesterol, and a decrease in the high-density lipoprotein (HDL) cholesterol concentration. These condition are mainly associated with cardiovascular or coronary heart disease. The other